heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-18. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
After opening his shop Thomas Lipton began travelling the world for new items to stock. Tea, historically a rare and expensive luxury, doubled in sales from £40 million in the late 1870s to £80 million by the mid-1880s. In 1890 Lipton purchased tea gardens in Ceylon, now Sri Lanka, from where he packaged and sold the first Lipton tea. He arranged packaging and shipping at low cost, and sold his tea in packets by the pound (454g), half-pound (227g), and quarter-pound (113g), with the advertising slogan: "Direct from the tea gardens to the teapot." Lipton teas were an immediate success in the United States. The Lipton tea business was acquired by consumer goods company Unilever in a number of separate transactions, starting with the purchase of the United States and Canadian Lipton business in 1938. The company owned 12% of the Lipton holding company, Allied Suppliers, a retail holding company, but had 33.7% of the voting rights. In 1972, Unilever sold its shares in Allied Supplies to Sir James Goldsmith's Cavenham Foods group for £10.4 million, on the understanding they could buy Lipton's tea business back at a price agree by an independent adjucator. The fee set was £18.5 million which Unilever completed the purchase of in August 1972. In 1991, Unilever created a joint venture with PepsiCo, the Pepsi Lipton Tea Partnership (PLTP), for the marketing of ready to drink teas in North America. This was followed in 2003 by a second joint venture, Pepsi Lipton International (PLI), covering many non-North American markets.
==== Extensive development of "wasting-thirst" (265–1368) ==== The diagnosis and treatment of xiāo kě was expanded significantly through the Sui (581–618) and Tang (618–907) dynasties. Zeng Liyan (545–649) expounded on the diagnosis of modern-day diabetes mellitus through the presence of sugar in the urine (glycosuria). This characterization was echoed by other physicians in the centuries that followed. Notably, in Wàitái Mìyào (外臺秘要; "Medical Secrets of an Official") written in 752, Wang Tao (fl. 8th century AD) included a detailed case report of sweet urine and a summary of diabetology history before the Tang dynasty. Sun Simiao (581–682 AD) further developed approaches to treatment, prevention, regulation, nursing, and convalescence. The formulae for wasting-thirst grew from one in The Yellow Emperor's Classic of Internal Medicine, to nine in Zhang Zhongjing's works, to 73 in Sun Simiao's. The selection of herbs grew from one (Eupatorium fortunei), to dozens used by Zhang, to over one hundred used by Sun.
==== Increasing endogenous production ==== Regular exercise is known to increase DHEA production in the body. Calorie restriction has also been shown to increase DHEA in primates. Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction.
Sources: en.wikipedia.org
=== Discovery === Ritonavir (initially designated as ABT-538) was developed through the systematic structural modification of A-80987, a moderately potent, symmetry-based HIV protease inhibitor. While A-80987 demonstrated good oral bioavailability, its clinical utility was limited by a very short circulating half-life. This rapid clearance was primarily driven by the oxidative metabolism (specifically N-oxidation) of its pyridyl end groups by cytochrome P450 enzymes in the liver and intestine.
Nigel Shaun Scrutton (born 2 April 1964) is a British biochemist and biotechnology researcher known for his work on enzyme catalysis, biophysics and synthetic biology. He is Director of the UK Future Biomanufacturing Research Hub, Director of the Fine and Speciality Chemicals Synthetic Biology Research Centre (SYNBIOCHEM), and Co-founder, Director and Chief Scientific Officer of the 'chemicals-from-biology' company C3 Biotechnologies Ltd. He is Professor of Enzymology and Biophysical Chemistry in the Department of Chemistry at the University of Manchester. He is a former Director of the Manchester Institute of Biotechnology (MIB) (2010 to 2020).
Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or tissue of origin as the root. For example, the most common cancer of the liver parenchyma ("hepato-" = liver), arising from malignant epithelial cells ("carcinoma"), would be called a hepatocarcinoma, while a malignancy arising from primitive liver precursor cells is called a hepatoblastoma. Similarly, a cancer arising from malignant fat cells would be termed a liposarcoma. For some common cancers, the English organ name is used. For example, the most common type of breast cancer is called ductal carcinoma of the breast. Benign tumors (which are not cancers) are usually named using -oma as a suffix with the organ name as the root. For example, a benign tumor of smooth muscle cells is called a leiomyoma (the common name of this frequently occurring benign tumor in the uterus is fibroid). Confusingly, some types of cancer use the -noma suffix, examples including melanoma and seminoma. Some types of cancer are named for the size and shape of the cells under a microscope, such as giant cell carcinoma, spindle cell carcinoma, and small-cell carcinoma.
Sources: en.wikipedia.org
As tribal healers developed into doctors, it spurred on a primitive pharmaceutical industry that included traders who would travel overseas bringing herbs that would be used for specific wounds. Soon, like most industries, patients began to skip the doctors altogether and purchased the herbs directly from the traders who were also aware of the effects and quantities that should be taken while also informing their "patients" of them. These merchants that supplied people with herbs were known as rhizotomiki, or gatherers of roots, in Ancient Greece. The earliest known list of herbs and remedies was probably written for these herbal merchants. The earliest known to men is the Rhizotomika of Diocles of Carustius, a student of Greek philosopher Aristotle. This book includes the author's observation of the effects of the herbal medicine on specific parts of the human body. This then became the beginning of scientific research on herbal remedies on humans, which has been modified and significantly changed from modern wound remedies. The Greeks also acknowledged the importance of wound closure, and were the first to differentiate between acute and chronic wounds, calling them "fresh" and "non-healing", respectively. Galen of Pergamum, a Greek surgeon who served Roman gladiators circa 120–201 A.D., made many contributions to the field of wound care. The most important was the acknowledgment of the importance of maintaining wound-site moisture to ensure successful closure of the wound.
== History == The Sinokrot family has worked in food products since 1982, when the company began manufacturing candies, chocolate, and other confectioneries in its first Ramallah factory. Sinokrot has also established the following ventures:
== Gases == Several substances that exist as gases at standard conditions of temperature and pressure are commonly used as concentrated aqueous solutions. To clarify that it is the gaseous form that is being referred to, the term anhydrous is prefixed to the name of the substance:
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。